News

Pooled findings indicate that the quality of life in patients receiving surufantinib for advanced neuroendocrine tumors was comparable to that of placebo.

Patients with neuroendocrine tumors across various origins experienced favorable responses after receiving tidutamab.

Kathy Burns, MS, APRN-CNS, AGCNS-BC, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, comments on the importance of being mindful about one’s implicit bias in the treatment of patients with cancer who have substance use disorders.

A study in France showed that patients with lung cancer, a population initially excluded from COVID-19 vaccination registration trials, were able to safely receive 3 doses.

David Hui, MD, MSc, from The University of Texas MD Anderson Cancer Center, discusses how caregivers may prioritize communication when making end-of-life sedation decisions for loved ones with agitated delirium.

“Each step along the way has really helped me grow professionally, not just as a clinician, but as a whole practitioner, to make my transition to practice a lot easier and make me more comfortable… it’s really an invaluable experience.”

Physicians urge patients with lymphoid malignancies to continue precautionary COVID-19 measures regardless of vaccination status.

The implementation of the HuCare Quality Improvement Strategy supported superior emotional function for patients newly diagnosed with cancer.

Data presented at the 2021 ASCO Quality Care Symposium demonstrated that in-person interactions had a bigger impact of professional satisfaction than financial stability.

The FDA approval of sirolimus protein-bound particles marks the first approved therapeutic option for patients with advanced PEComa.

Within this intense experience, caregivers can often find themselves physically and emotionally exhausted

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, discusses the importance of NCCN guidelines in prescribing medications for patients with chronic leukemia. .

A presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting shared updated findings on the efficacy of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.

The majority of patients who received telotristat ethyl to treat their carcinoid syndrome reported stable or increased weight at a 6-month follow-up.

Joe Contreras, MD, chair of the Institute of Pain and Palliative Medicine, explains how some common misconceptions may be hindering patients from receiving potentially outcome-improving palliative care.

Patients receiving immune checkpoint inhibitors for renal cell carcinoma or melanoma responded well to the COVID-19 vaccine.

Jessica MacIntyre, executive director of clinical operations at Sylvester Comprehensive Cancer Center, explains how the small market for experienced oncology nurse practitioners prompted their institution to design a successful Hematology/Oncology Nurse Practitioner Fellowship.

Pembrolizumab represents the first immunotherapy approved to treat patients with renal cell carcinoma in the adjuvant setting.

A total of 7.4% of patients received a secondary or downstream procedure within the 12 months following their lung cancer screening.

New research found that the discontinuation of prophylactic octreotide was not associated with an increased rate or duration of carcinoid crisis in patients with neuroendocrine tumors.

The director at the Center for Cancer Health Equity, The University of Ohio Comprehensive Cancer Center, discusses how the pandemic put a spotlight on issues of equity within the health care system.

Trilaciclib was associated with reduced chemotherapy-induced myelosuppression and the need for associated supportive care in patients with a subtype of lung cancer.

As nurses around the country weigh their professional options, some wonder if the answer resides in telling a white lie. But every choice has a consequence. What are the ramifications of lying on a religious exemption form?

Ropeginterferon alfa-2b-njft is now an FDA-approved drug for the treatment of polycythemia vera.

Nuanced and multidisciplinary decision making are needed to optimize and personalize locoregional, systemic, and supportive care in metastatic breast cancer.

An expert from NYU Langone outlines how checkpoint blockade approvals have helped advance endometrial cancer management.

David Hui, MD, MSc, from The University of Texas MD Anderson Cancer Center, discusses the impacts of personal sedation goals for caregivers of patients with cancer experiencing end-of-life agitated delirium.

The COVID-19 pandemic has demonstrated that personalized medicine should consider social determinants of health disparities as well as genomic factors.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, discusses omacetaxine as a novel regimen in CML treatment.

Patients with cancer should receive the entire COVID-19 vaccination as soon as possible, according to an expert at the 39th Annual Chemotherapy Foundation Symposium.